Celldex Therapeutics Inc (CLDX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Celldex Therapeutics inc   (NASDAQ: CLDX)


Celldex Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Celldex Therapeutics Inc 's ROA in the second quarter of 2026?
Celldex Therapeutics Inc recorded a cumulative net loss of $-301 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -47.62%.

However, within the Healthcare sector 550 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3888, from total ROA ranking in the first quarter of 2026 at 4433.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 13.48 % -30.68 % -26.18 % -21.18 % -18.35 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -301 -284 -259 -225 -200
Return On Assets (TTM) -47.62 % -46.66 % -38.94 % -31.35 % -26.28 %
CLDX's Total Ranking # 3888 # 4433 # 3794 # 3704 # 3674
Total Assets (TTM) in million 783 511 583 647 690
Seq. Total Assets Change 53.15 % -12.3 % -9.94 % -6.18 % -6.45 %
Seq. Net Income Change - - - - -

CLDX's 5 Years Annual ROA >> Back to CLDX Management Effectiveness >> Compare CLDX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 9
Sector # 551
Overall # 3868

Return On Assets Statistics
High Average Low
-18.96 %
-36.61 %
-87.16 %
(Dec 31 2024)   (Dec 31 2018)





Financial Statements
Celldex Therapeutics Inc 's Assets $ 783 million CLDX's Balance sheet
Celldex Therapeutics Inc 's Income $ -74 million Quarterly CLDX's Income Statement
CLDX's Income by Division See CLDX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -26.18 % 70.21 % 32.7 % -21.18 % 89.28 %
Total Assets in million 583 790 464 350 444
Y / Y Net Income Change - - - - -
Net Income in million -259 -158 -141 -112 -71
Annual Return On Assets -44.38 % -19.99 % -30.48 % -32.13 % -15.9 %

CLDX's 5 Years Annual ROA >> Back to CLDX Management Effectiveness >> Compare CLDX ROA to its Competitors



More Return On Assets Ratios
CLDX's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CLDX's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CLDX's Competitors
Subscribers only: Roa for Celldex Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CLDX's Customers

You may also want to know
CLDX's Roi CLDX's Inventory Turnover Ratio CLDX's Growth Rates CLDX's Dividend Comparisons
CLDX's Profitability Ratios CLDX's Asset Turnover Ratio CLDX's Dividend Growth
CLDX's Roe CLDX's Valuation Ratios CLDX's Financial Strength Ratios CLDX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-08T15:11:45+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.